Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Repaglinide composite medicine and preparation method thereof

A technology for drugs and adhesives, applied in the field of medicine, can solve the problems of the use of repaglinide, increase hypoglycemia, drug waste, etc., and achieve the effects of reducing production costs, accelerating metabolism, and preventing the level from rising too fast

Inactive Publication Date: 2019-07-26
南京瑄宇医药科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, repaglinide, like other hypoglycemic drugs, may cause hypoglycemia after taking it. Taking it in conjunction with other hypoglycemic drugs will increase the risk of hypoglycemia, which limits the use of repaglinide
In the preparation method of medicine, all the powders of various components are mixed and then uniformly produced. For the medicine ingredients that act successively, the mechanism of action of the medicine is not followed, which may cause waste of medicine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Repaglinide composite medicine and preparation method thereof
  • Repaglinide composite medicine and preparation method thereof
  • Repaglinide composite medicine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] A combination drug of repaglinide, comprising the following components in parts by mass:

[0056] Repaglinide 1 part;

[0057] 1 part of amobarbital;

[0058] 2 parts of water-soluble dietary fiber;

[0059] Glucose 0.2 parts;

[0060] 60 parts of filler;

[0061] 4 parts of disintegrant;

[0062] Adhesive 2 parts;

[0063] Arginine 2 parts.

[0064] specifically:

[0065] The water-soluble dietary fiber is lactoligosaccharide.

[0066] The filler is a composition of mannitol and microcrystalline cellulose, and the ratio of the mannitol to microcrystalline cellulose is 1:1 (including this ratio and the ratios described below are volume ratios).

[0067] The disintegrating agent is oligomeric hydroxypropyl cellulose.

[0068] The binder is a combination of povidone and hydroxypropyl methylcellulose, and the ratio of povidone and hydroxypropyl methylcellulose is 1:2.

[0069] The preparation method of the above-mentioned repaglinide combination medicine comprise...

Embodiment 2

[0076] A combination drug of repaglinide, comprising the following components in parts by mass:

[0077] Repaglinide 2 parts;

[0078] 1.5 parts of amobarbital;

[0079] 3 servings of water-soluble dietary fiber;

[0080] Glucose 0.3 parts;

[0081] 56 parts of filler;

[0082] 8 parts of disintegrant;

[0083] Adhesive 2 parts;

[0084] Arginine 1 part.

[0085] specifically:

[0086] The water-soluble dietary fiber is a mixture of xylooligosaccharide and hydroxymethylcellulose, and the ratio of xylooligosaccharide and hydroxymethylcellulose is 2:3.

[0087] The filler is mannitol.

[0088] The disintegrating agent is a composition of sodium hydroxymethyl starch and cross-linked sodium hydroxymethyl cellulose, and the ratio of sodium starch glycolate and sodium cross-linked hydroxymethyl cellulose is 1:1.

[0089] The binder is a combination of povidone, sodium hydroxymethylcellulose and hydroxypropylmethylcellulose, and their ratio is 1:1:2.

[0090] The preparatio...

Embodiment 3

[0097] A combination drug of repaglinide, comprising the following components in parts by mass:

[0098] Repaglinide 3 parts;

[0099] 2 parts of amobarbital;

[0100] 4 servings of water-soluble dietary fiber;

[0101] Glucose 0.4 parts;

[0102] 55 parts of filler;

[0103] 6 parts of disintegrant;

[0104] 3 parts adhesive;

[0105] Arginine 2 parts.

[0106] specifically:

[0107] The water-soluble dietary fiber is a mixture of lacto-oligosaccharides, xylo-oligosaccharides and pectin, and their ratio is 2:3:2.

[0108] The filler is a composition of microcrystalline cellulose and pregelatinized starch, and their ratio is 3:4.

[0109] The disintegrant is sodium hydroxymethyl starch.

[0110] The binder is hydroxypropyl methylcellulose.

[0111] The present invention also provides a preparation method of the repaglinide combination drug, which is characterized in that it comprises the following steps:

[0112] (I) Grinding and sieving: firstly crush and sieve each ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a repaglinide composite medicine and a preparation method thereof and belongs to the technical field of medicines. The medicine comprises, by mass, the following components: 1-5 parts of repaglinide, 1-3 parts of isopentobarbital, 2-5 parts of water-soluble dietary fiber, 0.2-0.5 part of glucose, 50-60 parts of a filler, 4-10 parts of a disintegrant, 1-3 parts of a binder and 1-3 parts of arginine. The preparation method comprises the steps of crushing, sieving, granulating, material wrapping preparation, material wrapping and granulating, forming and processing and thelike, and mainly comprises the steps of mixing glucose, a part of filler and a part of disintegrant to obtain core particles, and then wrapping other components, wherein a material wrapping and granulating device is adopted in the material wrapping and granulating operation, and the material wrapping and granulating device comprises a feeding and granulating mechanism, a wetting mechanism, a material wrapping mechanism and a discharging and granulating mechanism which are sequentially connected. The repaglinide composite medicine not only can provide a strong hypoglycemic effect, but also canprevent the possibility of increasing the side effect of hypoglycemia; the preparation method conforms to the requirement of drug action mechanism.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a repaglinide combination medicine and a preparation method thereof. Background technique [0002] Repaglinide is a new type of non-sulfonylurea short-acting oral insulin secretion-stimulating hypoglycemic agent. After repaglinide is absorbed through the stomach, it becomes a free active substance in the blood, which stimulates the release of insulin from the pancreas and rapidly lowers the blood sugar level. This effect depends on the functional β cells in the pancreatic islets. The difference from other oral insulin-stimulating hypoglycemic drugs is that it binds to the receptor on the β-cell, closes the APT-dependent potassium channel in the β-cell membrane, depolarizes the β-cell, opens the calcium channel, and makes the influx of calcium Increase, this process induces β cells to secrete insulin. It is used for type 2 diabetes whose high blood sugar cannot be effectively c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/48A61K9/20A61K47/38A61K47/26A61K47/36A61K47/18A61K31/451A61K31/515A61P3/10A61J3/00
CPCA61J3/00A61K9/1617A61K9/1623A61K9/1652A61K9/167A61K9/2013A61K9/2018A61K9/2054A61K9/2086A61K31/451A61K31/515A61P3/10A61K2300/00
Inventor 汪余胜钟俊生
Owner 南京瑄宇医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com